CCT6A alleviates pulmonary fibrosis by inhibiting HIF-1α-mediated lactate production
Journal of Molecular Cell Biology · 21.10.2024 · 16 (5)
DOI: 10.1093/jmcb/mjae021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Cell Biology, online erschienen am 17.05.2024. Verfasst von Peishuo Yan und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding…. Hauptthemen laut MEDLINE: Hypoxia-Inducible Factor 1, alpha Subunit, Lactic Acid, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, Key R&D Program of Henan Province, Henan Project of Science and Technology.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a lethal progressive fibrotic lung disease. The development of IPF involves different molecular and cellular processes, and recent studies indicate that lactate plays a significant role in promoting the progression of the disease. Nevertheless, the mechanism by which lactate metabolism is regulated and the downstream effects remain unclear. The molecular chaperone CCT6A performs multiple functions in a variety of biological processes. Our research has identified a potential association between CCT6A and serum lactate levels in IPF patients. Herein, we found that CCT6A was highly expressed in type 2 alveolar epithelial cells (AEC2s) of fibrotic lung tissues and correlated with disease severity. Lactate increases the accumulation of lipid droplets in epithelial cells. CCT6A inhibits lipid synthesis by blocking the production of lactate in AEC2s and alleviates bleomycin-induced pulmonary fibrosis in mice. In addition, our results revealed that CCT6A blocks HIF-1α-mediated lactate production by driving the VHL-dependent ubiquitination and degradation of HIF-1α and further inhibits lipid accumulation in fibrotic lungs. In conclusion, we propose that there is a pivotal regulatory role of CCT6A in lactate metabolism in pulmonary fibrosis, and strategies aimed at targeting these key molecules could represent potential therapeutic approaches for pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Organ Fibrosis, Pingyuan Laboratory, College o…
Förderung
- Ministry of Science and Technology of the People's Republic of China
- Key R&D Program of Henan Province
- Henan Project of Science and Technology
Zitieren
APA
Yan, P., Yang, K., Xu, M., Zhu, M., Duan, Y., Li, W., Liu, L., Liang, C., Li, Z., Pan, X., Wang, L., & Yu, G. (2024). CCT6A alleviates pulmonary fibrosis by inhibiting HIF-1α-mediated lactate production. Journal of Molecular Cell Biology, 16(5). https://doi.org/10.1093/jmcb/mjae021
Vancouver
Yan P, Yang K, Xu M, Zhu M, Duan Y, Li W, et al. CCT6A alleviates pulmonary fibrosis by inhibiting HIF-1α-mediated lactate production. Journal of Molecular Cell Biology. 2024;16(5). doi:10.1093/jmcb/mjae021
BibTeX
@article{Yan2024,
author = {Yan, Peishuo and Yang, Kun and Xu, Mengwei and Zhu, Miaomiao and Duan, Yudi and Li, Wenwen and Liu, Lulu and Liang, Chenxi and Li, Zhongzheng and Pan, Xin and Wang, Lan and Yu, Guoying},
title = {CCT6A alleviates pulmonary fibrosis by inhibiting HIF-1α-mediated lactate production},
journal = {Journal of Molecular Cell Biology},
year = {2024},
volume = {16},
number = {5},
doi = {10.1093/jmcb/mjae021}
}
EUVIMED